Clinical Trials

Are you a Minnesota resident with hypertrophic cardiomyopathy? This study aims to find out how common it is for people with hypertrophic cardiomyopathy to also have sleep apnea. Hypertrophic cardiomyopathy is a disease that causes the heart muscle to thicken. Participants will also wear a heart rhythm monitor to help researchers learn whether sleep apnea is linked to arrhythmia. The study seeks healthy volunteers as well as participants in the Hypertrophic Cardiomyopathy Registry. To participate in this study, you must not have had a catheter ablation procedure to treat atrial fibrillation, had surgery to replace your heart valves, or been treated for sleep apnea. The study is located in Rochester, Minnesota.

Have you been diagnosed with orthostatic intolerance? This study aims to find out how the body’s regulation of basic functions, such as heart rate and blood pressure, is altered in people who have orthostatic intolerance. This condition, which has an unknown cause, is characterized by a racing heartbeat, dizziness, lightheadedness, and other symptoms that occur when a person stands up. To participate in this study, you must be between 18 and 80 years old and have orthostatic intolerance. This study is located in Nashville, Tennessee.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Are you a female between 18 and 55 years old who has postural tachycardia syndrome (POTS)? This study is looking at the sympathetic nervous system and its effect on the increased heart rate and dizziness upon standing that people with POTS experience. This study is located in Nashville, Tennessee.

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect of medications. Prior activity studies required inpatient rehabilitation, which is impractical, hard to sustain, and poorly scalable to a rare disease.

The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.